Tag Archive: Revascularization

May 10

The US Food and Drug Administration (FDA) has recently approved vorapaxar

The US Food and Drug Administration (FDA) has recently approved vorapaxar, a protease–activated receptor 1 (PAR–1) inhibitor, to reduce the risk of MI, stroke, cardiovascular death, and need for revascularization in patients with a previous MI or peripheral artery disease.

Mar 19

Omega–3 fatty acid supplements have no benefit in reducing cardiovascular (CVD) risk

Omega–3 fatty acid supplements have no benefit in reducing cardiovascular (CVD) risk, reports a recent study published March 17 in JAMA Internal Medicine. It was observed that supplementing the diets of elderly patients with long–chain omega–3 fatty acids did not show any benefit in reducing CVD risk. Approximately five years of supplementation failed to reduce …

Continue reading »

Jan 25

Findings from a new post hoc analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE)

Findings from a new post hoc analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial led by Dr GB John Mancini(University of British Columbia, Vancouver suggest that coronary anatomy, and not ischemic disease burden, significantly predicts the risk of death, MI, and non–ST–elevation acute coronary syndrome (NSTE–ACS) in patients with stable …

Continue reading »